bNeisseria gonorrhoeae, the causative agent of the sexually transmitted infection gonorrhea, is not preventable by vaccination and is rapidly developing resistance to antibiotics. However, the transferrin (Tf) receptor system, composed of TbpA and TbpB, is an ideal target for novel therapeutics and vaccine development. Using a three-dimensional structure of gonococcal TbpA, we investigated two hypotheses, i.e., that loop-derived antibodies can interrupt ligand-receptor interactions in the native bacterium and that the loop 3 helix is a critical functional domain. Preliminary loop-derived antibodies, as well as optimized second-generation antibodies, demonstrated similar modest ligand-blocking effects on the gonococcal surface but different effects in Escherichia coli. Mutagenesis of loop 3 helix residues was employed, generating 11 mutants. We separately analyzed the mutants' abilities to (i) bind Tf and (ii) internalize Tf-bound iron in the absence of the coreceptor TbpB. Single residue mutations resulted in up to 60% reductions in ligand binding and up to 85% reductions in iron utilization. All strains were capable of growing on Tf as the sole iron source. Interestingly, in the presence of TbpB, only a 30% reduction in Tf-iron utilization was observed, indicating that the coreceptor can compensate for TbpA impairment. Complete deletion of the loop 3 helix of TbpA eliminated the abilities to bind Tf, internalize iron, and grow with Tf as the sole iron source. Our studies demonstrate that while the loop 3 helix is a key functional domain, its function does not exclusively rely on any single residue. N eisseria gonorrhoeae, the causative agent of the sexually transmitted infection gonorrhea (1), affects approximately 106 million people worldwide according to WHO estimates (2), with Ͼ300,000 cases of gonorrhea reported each year in the United States alone (3). A troubling contributor to these statistics is that infection with this bacterium does not result in any protective immunity (4). Additionally, approximately 50% of the women infected with the gonococcus are asymptomatic, resulting in increased spread and more severe clinical outcomes following infection (5). Most concerning of all is that the gonococcus has become increasingly drug resistant, with mounting evidence to suggest that current pharmacotherapies may soon be rendered obsolete (6, 7). To date, the characteristics of at least three multidrugresistant isolates have been published, all of which are fully resistant to ceftriaxone, the core component of the currently recommended combination therapy for the treatment of gonorrhea (7-11). With dwindling treatment options and no vaccine, gonorrhea is a serious public health concern that warrants further research.One approach to the development of therapeutics has been to study how the gonococcus acquires iron, an essential nutrient for nearly all microorganisms (12). During human infection, microorganisms are confronted with the challenge of obtaining iron in an environment that has evolved to specifically...